Aspirin for cholangiocarcinoma prevention: New targets to shift the dogma from ascertained risk to possible prevention

Hepatology. 2017 Mar;65(3):1075-1076. doi: 10.1002/hep.28999. Epub 2017 Feb 3.

Authors

Giovanni Brandi¹, Stefania De Lorenzo¹, Andrea Palloni¹, Guido Biasco¹, Francesco Tovoli¹

Affiliation

¹ Department of Experimental, Diagnostic, and Specialty Medicine, Universita degli Studi di Bologna Azienda Ospedaliera Sant'Orsola-Malpighi, Bologna, Italy.

PMID: 28010045
DOI: 10.1002/hep.28999

No abstract available

Publication types

Letter
Comment

MeSH terms

Aspirin*
Bile Duct Neoplasms
Bile Ducts, Intrahepatic
Cardiovascular Diseases
Cholangiocarcinoma*
Humans
Platelet Aggregation Inhibitors
Risk Factors

Substances

Platelet Aggregation Inhibitors
Aspirin